The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management has streamlined the business to focus exclusively on two high-impact markets—pharma and ag-chemicals—where its ChemPass AI engine provides a distinct competitive advantage.

The company's mission is now centered on designing novel, highly potent small molecules that are easier to synthesize and better aligned with target product profiles.

A key strategic pillar is the collaboration with Google to integrate AI agents into the ChemPass platform, aimed at automating the extraction of insights from scientific literature to build proprietary datasets.

The business model utilizes a dual-channel approach: establishing strategic partnerships to reduce financial risk and advancing an internal pipeline to secure better commercial terms later.

Pharma activities, launched only in early 2025, have rapidly expanded to four ongoing collaborations, demonstrating strong initial market validation for the AI-driven discovery platform.

Management believes that success in one segment, such as agriculture, serves as a proof of concept that accelerates engagement and credibility with partners in the pharmaceutical industry.

The company expects to advance its existing pharma and ag-chemical pipelines toward key value-creating milestones throughout the remainder of 2026.

Management is actively evaluating opportunities to establish a new internal drug development pipeline to complement its current collaborative projects.

In the agriculture sector, the company anticipates that its internal Septoria fungicide program will continue to show improved hit rates through iterative AI-driven design.

The Castor cultivation activity in Brazil is being positioned for a commercial launch, with sales of seeds expected to commence for the 2027 growing season.

Strategic discussions are ongoing with 'big pharma' and other technology giants similar to Google, though management notes that equity-linked strategic deals in pharma may take several quarters to materialize.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Evogene has terminated its research collaboration with Bayer for herbicide development due to inherent problems with the biology of the target protein, though the partnership validated the company's optimization capabilities.

The company is significantly scaling down or discontinuing non-core subsidiaries, including Lavie Bio and Biomica, to focus resources on the ChemPass AI platform.

A warrant inducement agreement in February 2026 resulted in $3.4 million in gross proceeds but also contributed to significant non-cash financial expenses due to accounting revaluations.

The company reported a consolidated cash position of approximately $13.1 million as of March 31, 2026, with additional cash inflows expected from subsidiary dividend distributions.

CEO Ofer Haviv identified the agriculture segment as the most likely area for a near-term strategic transaction that could include an equity component due to the maturity of the results.

He noted that while discussions with 'big pharma' have begun, significant equity-linked deals in the pharmaceutical space will likely require more advanced preclinical or clinical data from current collaborations.

The company is also exploring technology-focused partnerships with large-scale tech firms, similar to the existing Google collaboration, to further expand its computational lead.